Robert Paridaens

A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer

R. Charles Coombes, Emma Hall, Lorna J. Gibson et al. · New England Journal of Medicine · 2004 · 1.8K citations · Full text

Pharmacy, Endocrinology, Oncology +13

Large-scale genotyping identifies 41 new loci associated with breast cancer risk

Kyriaki Michailidou, Per Hall, Anna González‐Neira et al. · Nature Genetics · 2013 · 1.1K citations · Full text

Life Sciences, Genetics, Molecular Genetics +13

Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial

R. Charles Coombes, CF Snowdon, Robert Paridaens et al. · The Lancet · 2007 · 909 citations

Medicine, Endocrinology, Oncology +4

Five Years of Letrozole Compared With Tamoxifen As Initial Adjuvant Therapy for Postmenopausal Women With Endocrine-Responsive Early Breast Cancer: Update of Study BIG 1-98

Alan S. Coates, Aparna Keshaviah, Beat Thürlimann et al. · Journal of Clinical Oncology · 2007 · 904 citations

Medicine, Oncology, Breast Oncology +13

Associations of Breast Cancer Risk Factors With Tumor Subtypes: A Pooled Analysis From the Breast Cancer Association Consortium Studies

Xiaohong R. Yang, Jenny Chang‐Claude, Ellen L. Goode et al. · JNCI Journal of the National Cancer Institute · 2010 · 716 citations · Full text

Medicine, Cancer Biology, Oncology +16